ICR | GSK claims first positive Phase 3 result for an RSV vaccine

GSK claims first positive Phase 3 result for an RSV vaccine

GSK’s experimental vaccine for respiratory syncytial virus prevented disease in adults 60 and older, the company said Friday, clearing the way for the British drugmaker to ask regulators later this year to approve the shot.

The oldest independent membership-led professional body for clinical researchers across the globe.